A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia

NCT ID: NCT07256912

Last Updated: 2026-02-13

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 1266 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-15
• Study Completion Date: 2029-01-15

Brief Summary

The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months post vaccination. The vaccine will be given randomly to the boys and girls/women in these age group and they will be followed up to check the immune status developed in them after vaccination. The status of immune response developed by the two differnet vaccines will be compared in these group of participants of the study.

Conditions

Vaccine Effectiveness; HPV Vaccination; Single Dose; Immunogenicity; Cervical Cancer Prevention; Quadrivalent HPV Vaccine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

Girls/women and boys vaccinated with single dose CERVAVAC-4 vaccine

CERVAVAC-4 single dose vaccine will be administered - off label in one arm

Group Type: EXPERIMENTAL

quadrivalent HPV vaccine

Intervention Type: BIOLOGICAL

CERVAVAC-4 single dose vaccine

Girls/women and boys vaccinated with single dose Gardasil-4 vaccine

Gardasil-4 single dose vaccine will be administered in one arm

Group Type: ACTIVE_COMPARATOR

quadrivalent HPV vaccine

Intervention Type: BIOLOGICAL

Gardasil-4 single dose

Interventions

quadrivalent HPV vaccine

CERVAVAC-4 single dose vaccine

Intervention Type: BIOLOGICAL

quadrivalent HPV vaccine

Gardasil-4 single dose

Intervention Type: BIOLOGICAL

Other Intervention Names

CERVAVAC single dose; Gardasil-4 vaccine

Eligibility Criteria

Inclusion Criteria

1. Girl/woman between 9 and 20 years of age and boy between the age of 9 and 14 years at the time of recruitment.

2. Participant willing to sign a written informed consent (for participants 18 years of age and above).

3. Parent (s) willing to provide written informed consent and participant is willing to sign written assent form for participation (for participants below 18 years of age at the time of eligibility assessment).

4. Participant or parent (s) willing to comply with all study requirements.

5. Participants who are determined by Medical History (MH), Physical Examination (PE) and clinical judgment of the Investigator to be eligible for inclusion in the study.

Exclusion Criteria

1. Participants who are sexually active and missed their last menstrual period will have a urine pregnancy test and will be excluded if found pregnant.

2. Participant has a known history of prior vaccination with any HPV vaccine.

3. Participant known to be HIV positive (no routine HIV testing will be performed unless clinically indicated)

4. Participant currently enrolled in any other clinical studies of investigational products.

5. Participant with a current diagnosis or prior history of genital warts or treatment of genital warts.

6. Participant with a current diagnosis or prior history of cervical intraepithelial neoplasia (CIN) or cervical cancer.

7. Participant has a history of any allergic diseases or severe allergic reaction to any agent/vaccine product (e.g., swelling of the mouth and throat, difficulty in breathing, hypotension, or shock).

8. Participant has had an acute illness (moderate or severe) and/or fever (body temperature ≥ 38°C or ≥ 100.4 °F) at the time of vaccination or during the 72 hours prior to the vaccination.

9. Bleeding diathesis or uncontrolled condition associated with prolonged bleeding that would, in the opinion of the Investigator, contraindicate IM injection.

10. Participant has history of major congenital defects or illness that requires medical therapy, as determined by MH or clinical assessment.

11. Participant has had chronic administration (defined as more than 14 days) of high doses of corticosteroids (prednisone or equivalent at a dose of >0.5 mg/kg/day), cytotoxic agents or radiotherapy or immunoglobulins, immunosuppressants or other immune-modifying drugs in last 3 months or planned at any time during the study.

12. Participant has history of receiving a blood transfusion or other blood products in three months prior to screening.

13. Planned administration of a vaccine not foreseen by the study protocol within 14 days before and 14 days after any dose of study vaccine except TT given for emergency use and any vaccine mandated by government program.

14. Participant has history of any major pulmonary, cardiovascular, renal, neurological, metabolic, gastro-intestinal, hepato-biliary, hematological functional abnormality, mental or physical disability, blood dyscrasia or any condition which in the opinion of the Investigator might interfere with the evaluation of the study objectives.

15. Participant has history of any cancer, organ transplant or any other immune system disease.

16. Individuals who, in the opinion of the investigator, are unlikely to be compliant to all study procedures

• Minimum Eligible Age: 9 Years
• Maximum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

International Agency for Research on Cancer

OTHER

Sponsor Role: lead

Responsible Party

Ravivarman Lakshmanasamy

Public Health Officer

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Chipata and Matero First Level Hospitals

Lusaka, , Zambia

Countries

Zambia

Central Contacts

Ravivarman LAKSHMANASAMY, Dr

Role: CONTACT

lakshmanasamyr@iarc.who.int

+33 621507700

Facility Contacts

Groesbeck Parham

Role: primary

groesbeck.parham@icloud.com

260-978-124392

Other Identifiers

CervALONE Trial

Identifier Type: -

Identifier Source: org_study_id